NanoLogix (OTC: NNLX), an innovator in the accelerated detection and identification of microorganisms, announced today it will move its research and development operations from Cincinnati to its headquarters in Hubbard, Ohio. The company is converting a portion of its headquarters facility into a laboratory to house R&D operations.
"Following the announced closure of BioStart, the high-tech business incubator in Cincinnati where we operated a lab for five years, the decision was made to relocate our R&D operations to our Hubbard. We will now have all NanoLogix activities, R&D, production and management under one roof," said NanoLogix CEO, Bret Barnhizer. "This consolidation of operations is projected to be essentially seamless with incremental startup of the new lab in Hubbard coinciding with scale-down of Cincinnati operations. We expect the transition to be completed by September 30, 2011. The new Hubbard lab should result in an overall increase in efficiency and lower costs for both R&D and corporate operations."
This move comes at a point when the company is involved in several areas of work that continue to provide independent, third-party validation that NanoLogix technology is the fastest available for detection, identification and the determination of antibiotic sensitivity for live bacteria. In the area of healthcare applications, the company is expanding cooperation with the University of Texas Health Science Center-Houston, where its technology is being used in a 300-patient clinical trial. Additionally, NanoLogix is working on three projects with Battelle Biomedical Research Center covering the rapid detection and identification of numerous bacteria, including Salmonella, European E.coli, and Tuberculosis, to name a few. In drinking water monitoring, the company continues to develop a comprehensive water-quality test kit for drinking and source waters based upon the Cooperative Research and Development Agreement (CRADA) it has in place with the U.S. EPA.